> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Joint Panel to Review ADHD Drug
- URL: https://www.fdaweb.com/joint-panel-to-review-adhd-drug/
- Published: 2020-09-04T12:00:00.000Z
- Updated: 2026-09-14T16:27:47.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5147590

*Federal Register* notice: FDA has announced a 10/8 joint Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee meeting. Panel members are scheduled to review an Arbor Pharmaceuticals NDA for amphetamine sulfate immediate-release oral capsules and its proposed indication for treating attention deficit hyperactivity disorder. The product has been formulated with properties intended to deter non-oral abuse, and the applicant has submitted data to support the abuse-deterrent properties. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2020-09-04/pdf/2020-19562.pdf?ref=fdaweb.com).